StemCell Therapy

MINNEAPOLIS, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc.(POAI) (Predictive Oncology or the Company), focused on applying artificial intelligence (AI) to personalized medicine and drug discovery, today announced that it has received indications of interest from several parties for the possible acquisition of its Skyline Medical division, which produces and sells the STREAMWAY System for disposal of fluids in medical applications. As previously announced, Predictive Oncology has determined that it will focus its resources on its primary mission of applying artificial intelligence to precision medicine and drug discovery.

Skyline Medicals patented, FDA-approved STREAMWAY System is the first truly continuous, direct-to-drain fluid disposal system designed specifically for medical applications. The division has expanded sales globally and made significant inroads in U.S. markets.

Dr. Carl Schwartz, Predictive Oncologys Chief Executive Officer commented, I am exceptionally pleased with the rapid growth and development of our Helomics and Tumor Genesis divisions, as well as the multiple indications of interest for our Skyline Medical division. If this results in the sale of Skyline Medical, it would not only provide additional working capital, it would also allow Predictive Oncology to focus on the further development and commercialization of our two divisions focused on precision medicine.

The Company believes it will have updates on the future of its Skyline Medical business by early in 2020. The Company will evaluate its alternatives for the Skyline Medical business in order to maximize value for its stockholders. There is no assurance that the Company will ultimately receive offers for the division that it deems acceptable. Further, there is no assurance that the Company will enter into a definitive agreement or ultimately complete a sale of the division.

About Predictive Oncology Inc.

Predictive Oncology (POAI) operates through five segments (Domestic, International, Clinical, CRO and DCHIP), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform (D- CHIP) to provide a tailored solution to its clients specific needs. Predictive Oncologys TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially fools cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis Oncology Capture Technology Platforms which isolate and help categorize an individual patients heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncologys Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit http://www.predictive-oncology.com.

Forward-looking Statements

Certain of the matters discussed in the press release contain forward-looking statements that involve material risks to and uncertainties in the Companys business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include (i) risks related to the recent merger with Helomics, including the fact that the combined company will not be able to continue operating without additional financing; possible failure to realize anticipated benefits of the merger; costs associated with the merger may be higher than expected; the merger may result in disruption of the Companys and Helomics existing businesses, distraction of management and diversion of resources; and the market price of the Companys common stock may decline as a result of the merger; (ii) risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns; and (iii) other risks and uncertainties relating to the Company that include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; sales cycles that can be longer than expected, resulting in delays in projected sales or failure to make such sales; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; Predictives ability to implement its long range business plan for various applications of its technology; Predictives ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of Predictives technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Companys reports filed with the SEC, which are available for review at http://www.sec.gov. This is not a solicitation to buy or sell securities and does not purport to be an analysis of Predictives financial position. See Predictives most recent Annual Report on Form 10-K, and subsequent reports and other filings at http://www.sec.gov.

Story continues

Read more here:
Predictive Oncology Confirms Indications of Interest for Skyline Medical Business - Yahoo Finance

The GenomeAsia 100K consortium analyzed the genomes of 1,739 people, which represents the widest coverage of genetic diversity in Asia to date.

The study covers 64 different countries and provides what the authors call the first comprehensive genetic map for Asia that will guide scientists in studying diseases unique to Asians, improve precision medicine and identify drugs that may carry higher risk of adverse reactions for certain ethnic groups.

Despite forming over 40 per cent of the worlds population, Asian people have previously accounted for only six per cent of the worlds recorded genome sequences.

The goal of GenomeAsia 100K, which launched in 2016, is to better understand the genome diversity of Asian ethnicities by sequencing 100,000 genomes of people living in Asia. It is a non-profit consortium hosted by Nanyang Technological University, Singapore (NTU Singapore), the only academic member. Its three other members are Macrogen based in South Korea, Genentech, a member of the Roche Group in United States, and MedGenome from India/US.

NTU Professor Stephan C. Schuster, the consortiums scientific chairman and a co-leader of the study, explained the significance of GenomeAsia 100Ks initial findings on the vast genomic diversity in Asia: To put it into context, imagine we looked at all people of European and based on the level of their genetic diversity, observed that they could all be grouped into just one ancestral lineage or population. Now, if we took that same approach with our new data from people of Asian, then based on the much higher levels of genetic diversity observed we would say that there are 10 different ancestral groups or lineages in Asia.

Schuster added, GenomeAsia 100K is a significant and far-reaching project that will affect the well-being and health of Asians worldwide, and it is a great honour for Singapore and NTU to be hosting it.

Executive Chairman of GenomeAsia 100K, Mahesh Pratapneni said, The publication of this pilot study is a first milestone for GenomeAsia 100K, which is an unprecedented collaboration between academia and industry leaders in the field of genomics. We are certain more partners will join GenomeAsia 100K to accelerate medical breakthroughs for people of Asian heritage.

Chairman and CEO of MedGenome, the largest genomics and molecular diagnostics provider in South Asia with facilities in the US, Singapore and across India, Sam Santhosh, said, "We are excited that over 1000 whole genome sequence data from the Indian sub-continent will now be available to researchers; this is an initial step in covering the underrepresented geographies."

Prof Jeong-Sun Seo, at Seoul National University Bundang Hospital Consortium scientific co-chair and Chairman of Macrogen, said, I hope this Asian-focused study serves as a stepping stone for the democratization of health care and precision medicine in Asia.

How the database of Asian genomes was formed

Over the course of the last three decades prior to the pilot project, thousands of blood and saliva samples have already been collected by scientists and anthropologists from donors across Asia in hopes that one day, a deeper analysis to gain insights into the Asian community can be done.

Of particular interest were participants from remote and isolated communities, who have long been the subjects of study by anthropologists but have not yet undergone genomic analysis, until the GenomeAsia 100K project was kickstarted.

The pilot study included 598 genomes from India, 156 from Malaysia, 152 from South Korea, 113 from Pakistan, 100 from Mongolia, 70 from China, 70 from Papua New Guinea, 68 from Indonesia, 52 from the Philippines, 35 from Japan, and 32 from Russia.

Genomic DNA extracted from the blood and saliva samples was then sequenced in laboratories of the four consortium members in the US, India, South Korea and Singapore. The digital sequencing data were subsequently sent to Singapore for processing and storage.

Singapore was selected by the consortium as the host, as the country offered good travel connections for collaborating scientists, strong supercomputing facilities to crunch the data, and the required cybersecurity standards in its data centre for handling sensitive genetic data.

The combined data was compiled and analyzed by NTU scientists, including Assistant Professor Hie Lim Kim, a population genomics expert at the Asian School of The Environment, with the help of the National Supercomputing Centre Singapore (NSCC) and international collaborators.

Different Asian ethnic groups respond differently to mainstream drugs

Every person has approximately 3.2 billion different nucleotides, or building blocks, in their genome, which form their DNA code.

Its estimated that for the genomes of any two people, 99.9 per cent of this code is the same and on average, 0.1 per cent or three million nucleotides, are different between them.

This genetic variance help humankind colonize the most diverse environments on the planet and make it resilient to disease, but it also results in differential response to many medicines.

Genetic variance is the reason we are distinctively different from each other including differences in the diseases that each of us suffer from during our lifetimes. Understanding these differences is the most important source of clues that we have for driving the discovery of innovative new medicines, said Dr Andrew Peterson, an author of the paper and an expert in the use of genetics to drive drug discovery.

Peterson was head of Molecular Biology at Genentech while this work was being carried out, is now Chief Scientific Officer at MedGenome, where he leads drug discovery efforts at MedGenomes Seven Rivers Genomic Medicines division.

The frequencies of known genetic variants related to adverse drug response were analyzed for the genomes collected in this study.

For example, warfarin, a common anticoagulant drug prescribed to treat cardiovascular diseases, likely has a higher than usual risk of adverse drug response for people carrying a certain genetic variant. This particular genetic variant has a higher frequency to appear in those with North Asian ancestry, such as Japanese, Korean, Mongolian or Chinese.

Using data analysis, scientists can now screen populations to identify groups that are more likely to have a negative predisposition to a specific drug.

Knowing a persons population group and their predisposition to drugs is extremely important if personalized medicine is to work, stressed Prof Schuster: For precision medicine to be precise, you need to know precisely who you are.

Hie Lim Kim, who leads the projects efforts in population genetics, added: Only by sequencing the entire genome of an individual can a persons ancestry and genetic background be known. Their genome explains why some people are afflicted by certain diseases while others arent. Scientists know that there is no single drug that works well for everybody and our latest findings not only reinforce this, but suggest how specific groups could be harmed by specific medicines.

Moving forward, the GenomeAsia 100K will continue to collect and analyze up to 100,000 genomes from all of Asias geographic regions, in order to fill in the gaps on the worlds genetic map and to account for Asias unexpected genetic diversity.

Reference

GenomeAsia100K Consortium. (2019) The GenomeAsia 100K Project enables genetic discoveries across Asia. Nature. DOI: https://doi.org/10.1038/s41586-019-1793-z

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See more here:
Insights into Asian Ancestry and Genetic Diversity - Technology Networks

BETHESDA, Md., Dec. 4, 2019 /PRNewswire/ --The American College of Medical Genetics and Genomics (ACMG) heads to a new destination in sunny San Antonio, Texas in 2020. Named one of the fastest growing meetings in the USA by Trade Show Executive Magazine, the ACMG Annual Clinical Genetics Meeting continues to provide groundbreaking research and news about the latest advances in genetics, genomics and personalized medicine. To be held March 17-21, the 2020 ACMG Annual Meeting will feature more than 40 scientific sessions, 3 Short Courses, workshops, TED-Style talks and satellite symposia, and over 800 poster presentations on emerging areas of genetic and genomic medicine.

Interview those at the forefront in medical genetics and genomics, connect in person with new sources and get story ideas on the clinical practice of genetics and genomics in healthcare today and for the future. Learn how genetics and genomics research is being integrated and applied into medical practice.

Topics include gene editing, cancer genetics, molecular genomics, exome sequencing, pre- and perinatal genetics, biochemical/metabolic genetics, genetic counseling, health services and implementation, legal and ethical issues, therapeutics and more.

Credentialed media representatives on assignment are invited to attend and cover the ACMG Annual Meeting on a complimentary basis. Contact Kathy Moran, MBA at kmoran@acmg.net for the Press Registration Invitation Code, which will be needed to register at http://www.acmgmeeting.net.

Abstracts of presentations will be available online in January 2020. A few 2020 ACMG Annual Meeting highlights include:

Program Highlights:

Cutting Edge Scientific Concurrent Sessions:

Three half-day Genetics Short Courses on Monday, March 16 and Tuesday, March 17:

Photo/TV Opportunity: The ACMG Foundation for Genetic and Genomic Medicine will present bicycles to local children with rare genetic diseases at the Annual ACMG Foundation Day of Caring on Friday, March 20 from 10:30 AM 11:00 AM at the Henry B. Gonzlez Convention Center.

Social Media for the 2020 ACMG Annual Meeting: As the ACMG Annual Meeting approaches, journalists can stay up to date on new sessions and information by following the ACMG social media pages on Facebook,Twitter and Instagram and by usingthe hashtag #ACMGMtg20 for meeting-related tweets and posts.

Note be sure to book your hotel reservations early.

The ACMG Annual Meeting website has extensive information at http://www.acmgmeeting.net.

About the American College of Medical Genetics and Genomics (ACMG) and the ACMG Foundation for Genetic and Genomic Medicine (ACMGF)

Founded in 1991, the American College of Medical Genetics and Genomics (ACMG) is the only nationally recognized medical society dedicated to improving health through the clinical practice of medical genetics and genomics and the only medical specialty society in the US that represents the full spectrum of medical genetics disciplines in a single organization. The ACMG is the largest membership organization specifically for medical geneticists, providing education, resources and a voice for more than 2,300 clinical and laboratory geneticists, genetic counselors and other healthcare professionals, nearly 80% of whom are board certified in the medical genetics specialties. ACMG's mission is to improve health through the clinical and laboratory practice of medical genetics as well as through advocacy, education and clinical research, and to guide the safe and effective integration of genetics and genomics into all of medicine and healthcare, resulting in improved personal and public health. Four overarching strategies guide ACMG's work: 1) to reinforce and expand ACMG's position as the leader and prominent authority in the field of medical genetics and genomics, including clinical research, while educating the medical community on the significant role that genetics and genomics will continue to play in understanding, preventing, treating and curing disease; 2) to secure and expand the professional workforce for medical genetics and genomics; 3) to advocate for the specialty; and 4) to provide best-in-class education to members and nonmembers. Genetics in Medicine, published monthly, is the official ACMG peer-reviewed journal. ACMG's website (www.acmg.net) offers resources including policy statements, practice guidelines, educational programs and a 'Find a Genetic Service' tool. The educational and public health programs of the ACMG are dependent upon charitable gifts from corporations, foundations and individuals through the ACMG Foundation for Genetic and Genomic Medicine.

Kathy Moran, MBAkmoran@acmg.net

View original content to download multimedia:http://www.prnewswire.com/news-releases/press-registration-for-the-2020-acmg-annual-clinical-genetics-meeting-is-now-open-300969157.html

SOURCE American College of Medical Genetics and Genomics

Continue reading here:
Press Registration for the 2020 ACMG Annual Clinical Genetics Meeting Is Now Open - P&T Community

LAGUNA HILLS, Calif., Dec. 5, 2019 /PRNewswire/ --Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early stage breast cancer, announced today the official appointment of David J. Dabbs, MD, a world renowned expert in breast pathology, to its medical team to provide pathology leadership for both currently marketed tests and services and others in development.

Dr. Dabbs joins PreludeDx with over 30 years of experience in direct patient care and clinical research at university-based pathology practices. He has educated hundreds of pathologists globally through his previous academic appointments including most recently as Professor and Chief of Pathology at Magee-Women's Hospital of UPMC, Pittsburgh, PA. He has ledpresentations at key international medical meetings and co-authored textbooks which have become the diagnostic standard in pathology, Breast PathologyandDiagnostic Immunohistochemistry (Elsevier, New York). Dr. Dabbs has advanced the field of breast pathology and the cancer community's understanding of ductal carcinoma in situ (DCIS) and breast cancer by publishing over 200 papers in peer-reviewed medical journals.

In addition to providing pathology guidance for the company's DCISionRTtest and future developments, Dr. Dabbs will lead Prelude's newly launched second opinion service, BREAST SOS, a consultation service designed for patients and the breast care team. "I am first and foremost a fierce patient advocate. My role with PreludeDx will be to help patients through the work we do today and by guiding the on-going development and validation of new approaches for women diagnosed with DCIS and early stage breast cancer," Dabbs said. "I believe precision medicine requires precision information. Both DCISionRT and BREAST SOS add clarification and needed information to help clinicians and patients make the right decisions about individual patient care."

Daniel Forche, President and CEO of PreludeDx, stated, "We are honored to have David join us to apply his mastery and experience in breast cancer diagnosis, biomarker development and patient care. His addition to the team further supports the principles upon which we were founded; Patient Focus, Quality First and Driving Innovation. Every patient should have access to an expert second opinion, and with Dr. Dabbs at the helm of BREAST SOS, we can help make this a reality for women around the world by providing expertise and clarification during their time of need."

About David J. Dabbs, MD

David J. Dabbs, MD is a thought leader in breast pathology. He has published over 200 papers and has several editorial board appointments and responsibility for peer review of pathology journals. He completed his medical degree at Medical College of Ohio, and his residency and fellowship at University of Washington and Affiliated Hospitals. Dr. Dabbs served as Director of Anatomic Pathology, and Chief of Pathology, Magee-Women's Hospital of UPMC, Pittsburgh, PA for over 15 years. Most recently, he was Professor of Pathology, University of Hawaii Cancer Center, John A. Burns School of Medicine. He is certified by the American Board of Pathology for Anatomic Pathology and Cytopathology.

About DCISionRT for Breast DCIS

DCISionRT is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit. In the US, over 60,000 women are newly diagnosed with DCIS each year. The test was developed by PreludeDx and built on research that began with funding from the National Cancer Institute to better understand the biology of DCIS. DCISionRT assesses a woman's individual tumor biology along with other risk factors to provide a personalized recurrence risk. The test provides a Decision Scorethat identifies a woman's risk as low or elevated. DCISionRT's intelligent reporting provides a woman's recurrence risk after breast conserving surgery alone and with the addition of radiation therapy. In turn, this new information may help patients and their physicians to make more informed treatment decisions.

About PreludeDx

PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide. Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on developing precision breast cancer tools that will impact a patient's treatment decision. Our mission is to provide patients and physicians with innovative technologies that improve patient outcomes and reduce the overall cost burden to the healthcare system. Before making a treatment decision, Know Your Risk.

For more information on how PreludeDx is making a difference for patients, please visit the Company's website: http://www.preludedx.com

PreludeDx, the PreludeDx logo, DCISionRT, the DCISionRT logo, Decision Score, The DCIS Test, Know Your Risk and Your Biology, Your Decision are trademarks of Prelude Corporation or its wholly owned subsidiaries in the United States and foreign countries.

SOURCE PreludeDx

https://www.preludedx.com

Go here to read the rest:
PreludeDx Announces David J. Dabbs, MD as Chief of Pathology and Director of BREAST SOS (Second Opinion Service) - PRNewswire

Not long after announcing a wide-ranging partnership with Microsoft to bring artificial intelligence tools to every desk across its R&D departments, Novartis is now teaming up with Amazons mammoth cloud computing division to overhaul its manufacturing, supply and business operations.

The new multiyear collaboration with Amazon Web Services dovetails with the drugmakers directives to embrace and incorporate digital technology at every point in its product pipeline and value chain.

AWS aims to supply the company with an enterprisewide data analytics platform, including AI and machine learning services, as well as cloud-based Insight Centers that will provide real-time metrics to Novartis global technical operations staff.

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

These centers will focus on tracking manufacturing lines and detecting bottlenecks as well as forecasting potential issues in quality and inventory. Novartis hopes this will allow for new, optimized production models, as the company looks to scale up its work in challenging-to-make personalized medicines such as Zolgensma and Kymriah.

Most recently, company opened a new cell and gene therapy manufacturing facility last week in Stein, Switzerland, providing a European base of operations for tailored therapies. Previously, Novartis had to rely on back-and-forth flights across the Atlantic to service patients on the continent, with its sole Kymriah-producing facility being located in New Jersey.

RELATED: Novartis to put AI on every employee's desk through Microsoft partnership

Novartis also plans to use AWS internet of things and computer vision offerings to help improve its manufacturing inspections, by digitally scanning images of sites and tracking individual items to spot for potential risks or delays.

There is a lot we can learn from the AWS team, and while manufacturing is a great starting place, were keen to also explore where else we can apply this technology, Novartis chief digital officer, Bertrand Bodson, said in a statement.

Using data science and digital technologies to reimagine the way we manufacture medicines is not only at the heart of our transformation, but also core to our ambition to bring innovative medicines to patients faster, Bodson added.

RELATED: Novartis' Sandoz goes digital from back office to 'not just apps,' therapeutics

Novartis currently operates more than 60 manufacturing sites worldwide, producing treatments used by nearly 1 billion people. Through its partnership with AWS, the drugmaker hopes to develop standard metrics for site efficiency, deliverable on a single dashboard illustrating global performance.

The company has already been using Amazons computer vision products to double-check that batch manufacturing lines are clear and cleaned after use, and prepared to begin their next scheduled set of tasks. Novartis is also employing AI to extract and analyze data from printed manufacturing documents.

The forthcoming site-based Insight Centers look to make these data available in real time to help avoid unnecessary inventory and machine downtime when producing small-batch and personalized treatments.

More:
Novartis' digital transformation continues apace with Amazon supply chain tie-up - FierceBiotech

Industrial conglomerate General Electric hosted an investor teach-in in Chicago at a medical conference on Monday. The company reviewed its health-care franchise in a post-biopharma world. GE is selling its biopharma business to Danaher for $21 billion. Now investors have to evaluate the growth and margin potential of what is left.

GE Healthcare is a large global medical device company, said division CFO Monish Patolawala at the event. $17 billion in revenue, midteen margins with strong free cash flow conversion, with good opportunity to continue organic growth and margin expansion while still delivering good free cash flow conversion.

GEs case for its division is health care is a good franchise with solid profitability and decent growth. Bearish analysts dont see it that way.

We come away from the GE Healthcare investor day with no change to our negative view, wrote J.P. Morgan analyst (and known GE bear) Stephen Tusa in a Tuesday research report. While we believe this is an OK asset that has some opportunity to be managed better, we were underwhelmed by [the] presentation.

In particular, Tusa believes low research and development spending is a problem for the division. That theme was picked up by another bearish analyst, Gordon Hasketts John Inch.

Siemens reps at the show expressed pride in the companys outsized R&D budget and new product development, wrote Inch, contrasting GEs R&D spending with its rival Siemens Healthineers (SHL.Germany). For instance, Siemens talked about Dual Source CT scanner which is a technology that Siemens invented years ago but that competitors are just introducing.

GE management pointed out that a larger portion of its health-care business is in servicesfixing the installed based of diagnostic products. That skews the R&D as a percentage of sales comparisons, according to the company.

RBC analyst Deane Dray likes the service business mix. We liked hearing that recurring revenues account for 45% of health cares mix, Dray wrote following the event. And leverage to ongoing trends such as digital [and artificial intelligence] solutions and demand for precision health, which helps tackle waste in the health care industry and improve the accuracy of diagnostics. GE management spent a lot of time laying out how computing power is helping health-care professionals save time and how new technologies create opportunities for personalized medicine.

Tusa and Inch both rate GE shares the equivalent of sell with $5 and $7 price targets, respectively. Dray, on the other hand, rates shares buy and has a $14 price target for the stock.

GEs Healthcare Investor day highlighted the companys diversified global health care portfolio, wrote Citigroup analyst Andrew Kaplowitz. He focused on the outlook for health care in his research report. Despite a lower organic growth [and operating profit] margin profile following the pending sale of BioPharma, [GE Healthcare] could remain well positioned to contribute to growth over time.

The biopharma business has higher margins than the rest of GE Healthcare, which sells large, heavy diagnostic equipment. Kaplowitz is another bull and rates GE shares the equivalent of Buy, with a $14 price target.

Credit Suisse analyst John Walsh sums up the divide between bulls and bears by taking a middle path. We think GE Healthcare management presented a credible growth plan that should be enhanced by margin expansion and greater [free cash flow generation], wrote Walsh, who rates shares Hold. He sees a decent franchise with upside for shareholders if management can improve profitability.

One thing GE management didnt address in Chicago was the potential for a future health-care initial public offering. That was the plan for the division before the biopharma units sale was announced. The $21 billion coming in from that sale eliminated the need to raise money by selling GE Healthcare shares to the public. Now analysts wonder if an IPO is still in the cards.

GE stock dropped Monday and is down again Tuesday, by about 2.7%. Any health-care disappointment or IPO uncertainty, however, isnt the likely culprit. More bad trade news has all industrial stocks lower. On Monday, President Donald Trump threatened tariffs on Brazil, Argentina, and France. Tuesday, he said he might wait until after the election to strike a trade deal with China.

For the year, GE shares are up about 50% year, far better than comparable gains of the S&P 500 index and Dow Jones Industrial Average over the same span.

Write to Al Root at allen.root@dowjones.com

See the original post:
GE Is Touting Its Health-Care Business, but It Isnt Helping the Stock - Barron's

Getting a blood draw is a standard first step toward almost any medical diagnosis whether your doctor is concerned that you are anemic, have kidney disease or diabetes, or as part of a standard screening during pregnancy. Most of these tests check for a shortage or excess of a particular factor (often a protein) in the blood, which acts as a clue for physicians about a potential health risk.

But what if instead of needing a different blood draw for each suspected health issue, doctors could order up a single blood test that would combine a hundred or more different measures to reveal a holistic portrait of your overall health as well as your risk for a whole host of diseases? Such a test could be administered widely to inform early individualized interventions designed to keep everyone healthy longer.

This is the dream of UC San Francisco physician Peter Ganz, M.D., and colleagues at Colorado-based SomaLogic Inc., who are developing what they call liquid health check technology a single blood test capable of painting a detailed portrait of a persons current health and future disease risks. The technology uses tiny fragments of DNA and RNA called aptamers that are able to identify and measure thousands of different circulating proteins from a small blood sample to reveal information about the health of organs across the body.

In a proof-of-concept study published Dec. 2, 2019, in Nature Medicine, researchers led by Ganz and scientists at SomaLogic and the University of Cambridge, measured the levels of 5,000 different proteins in archived blood plasma samples from nearly 17,000 individuals participating in five different longitudinal health studies. This yielded a total of 85 million protein measurements, making this the largest such study to date, the authors say.

Applying sophisticated machine learning computer algorithms to this massive data set revealed protein expression patterns that correlated with 11 different measures of patients overall health and their risk of developing certain diseases in the years following the initial blood draw. For example, the test could predict how much fat a persons liver contained (associated with liver cirrhosis as well as cardiovascular disease and insulin resistance), their overall level of physical fitness, or whether they later suffered a heart attack or developed diabetes.

We spoke with Ganz who is Maurice Eliaser Distinguished Professor of Medicine at UCSF and director of the Center of Excellence in Vascular Research at Zuckerberg San Francisco General Hospital and Trauma Center about the new study, and about his hopes for liquid health check technology to advance personalized precision medicine. (See the news release by Cambridge University for more details on the study.)

What is a liquid health check and what is your vision for the potential of this technology to improve patients health?

We coined the term liquid health check to refer to information about a persons risks of future diseases, current states of health and modifiable behaviors that can be discerned entirely from different patterns of proteins in blood.

Many people have used blood protein measurements to predict the risk of one disease at a time, but the idea of a liquid health check is to use protein scanning on a large scale to simultaneously predict the risk of numerous diseases and holistically identify an individuals state of health from head to toe.

The results of our studies show that scanning the levels of thousands of blood proteins can simultaneously capture the necessary information to deliver a one-stop test for personalized detection, prevention and treatment of many diseases. This would certainly be much more convenient and likely much less expensive than needing multiple rounds of clinical visits and tests to track down something thats going wrong in your body.

In our newest proof-of-concept study, we were able to predict 11 different kinds of health information about our participants, just by looking at proteins in their blood. Ultimately, our goal is to predict more than 100 diseases or states of health from a single blood sample, which would really be a new paradigm for a blood test.

Which types of health conditions are most amenable to evaluation through a blood test?

From all the studies conducted with blood protein scanning to date, there is evidence that protein patterns can pinpoint propensity for heart disease, diabetes, liver disease, kidney disease, cognitive brain impairment and cancer. We hope that we will ultimately find protein signatures for diseases that afflict most if not all human organs and tissues.

As a cardiologist, how did you get involved in the development of this technology?

I spent most of my career at Brigham and Womens Hospital in Boston as a cardiologist studying human endothelial biology. When I came to UCSF in 2008, I wanted to do something different, but didnt know what it would be. I was introduced to the chief medical officer of SomaLogic quite serendipitously, but I came out of that meeting with my eyes opened about the potential of the technology they were developing.

I have been on their Medical Advisory Board ever since I dont take any money from them or any other company and have basically helped to guide the development of clinical applications of their technology.

The ability to analyze blood proteins and link them to human disease is going to be a critical tool of the precision medicine revolution.Peter Ganz, M.D.

Initially we focused on cardiovascular applications, in part because of my background, and in 2016 we published a study in JAMA where we used the technology to predict the future risk of heart attacks, strokes, heart failure and death based on nine different blood proteins.

After that paper, we decided that with a technology that can measure 5,000 proteins simultaneously in a sample of blood, why underutilize this platform, measuring just nine proteins to inform cardiovascular outcomes? We talked about how we could take advantage of a platform that could measure so many different proteins, and thats how we arrived at the idea of developing liquid health checks a holistic approach to disease prevention and management that is not constrained by any one specialty.

How are you collaborating with SomaLogic to develop liquid health check technology? How have new technologies made this vision possible?

This project represents an exemplary collaboration between academic institutions and an industry partner. SomaLogic has developed a unique technology to quantify thousands of blood plasma proteins at once, while my academic colleagues and I have played a key role in linking blood protein patterns to propensity for developing illnesses or for maintaining good health in studies that have required participation of many thousands of patients worldwide.

The ability to analyze blood proteins and link them to human disease is going to be a critical tool of the precision medicine revolution. In fact, these protein scans are not just a fantasy in the distant future. A limited initial release version of the protein test is now available for clinical use.

One thing I think is very important for establishing confidence in this technology is that we are all dedicated to openness and transparency. From the get-go we agreed that everything thats learned will be published, and weve even pushed journals to publish hundreds of pages of supplementary materials to ensure that anyone who wants to can replicate our results.

Disclosures: Dr Ganzs proteomic research is supported by National Institutes of Health grants 1RO1HL129856, 1UO1DK108809, and 1R01AG052964. Dr. Ganz serves on the medical advisory board to SomaLogic Inc., for which he accepts no salary, honoraria, or any other financial incentives.

Read more here:
Toward a head-to-toe health check from a single blood test - University of California

According to the latest study conducted byMarket Growth Analysisthe global market for precision medicine is anticipate grow manifold, reflecting a robust CAGR of over XX% during 2018 to 2025.

Rapid augmentation of the medicine industry across the globe will certainly benefit the global market for precision medicine. In addition, factors such as growing infrastructural development, higher investments, streamlined drug approval systems along with companion diagnostics are expected to favor the overall market growth during the assessment period. Cost-effective DNA profiling and increasing prevalence of carcinogenic diseases worldwide are additional factors that are projected to propel the market growth. Moreover, apt storage of genome data is of great significance to the global market for precision medicine as demand for data medicare is on the rise. However, acute data storage capacity, data privacy breach and discrepancies in funding systems and hefty price tag of personalized drugs may deter the market growth in the near future.

Request a Report Sample with Toc and figures to click here: http://marketgrowthanalysis.com/reports/sample/436

The global market for precision medicine has been categorized into various parent segments that are further segmented into smaller sub-divisions.

On the basis of technology, next-gen sequencing, bioinformatics and drug discovery technology are expected to be the technologies highlighting the expanding the market width in forthcoming years. Based on applications, the oncology segment is expected to witness an overwhelming growth and is estimated to reach US$ XX Billion over 2025, reflecting a staggering XX% CAGR. This is primarily owing to increasing prevalence of tumor-related disease amongst the global geriatric population. On the other hand, increasing cases of arthritis will favor the growth of immunology segment, which is expected to surpass US$ XX Million in revenues by 2025 end.

Vendor News

Key players operating in the global market for precision medicine include Eli Lilly And Company, Novartis AG, AstraZeneca and Laboratory Corporation of America Holdings. Most of the companies are implementing market strategies involving mergers, tie-ups and acquisitions. Increasing collaboration between healthcare and IT is expected to deliver fruitful gains to the market, expanding the overall business canvas for the stakeholders in the upcoming years.

Request for enquiry on This Report at: http://marketgrowthanalysis.com/reports/enquiry/436

The popularity of precision medicine has grown significantly across various parts of the world, hence on the basis of region, the markets for precision medicine in Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa (MEA) is set to achieve new figures of growth over the next eight years. Precisely, the market in North America is expected to present new lucrative opportunities, occupying over XX% share of the market during the forecast period. In addition, the region is estimated to surpass a market valuation of over US$ XX Million by the end of 2025.

The US and Canada will be the heavyweights of the global market owing to the existence of well-established medical industries in both the countries. In Europe, the market is expected to witness a steady growth and will increase its revenues charts close to US$ XX Million, riding on a healthy CAGR of over XX% during the assessment period. This is largely due to the increasing demand for precision medicines in countries such as France, UK, Italy and Germany. The Asia Pacific region is another region which is considered to be full of business potentials. The region is projected to increase at over XX% CAGR to reach approximately US$ XX Million by 2025 end. The market in APAC will be heavily dominated by Japan, while, India and China will compete for the second spot. Likewise, the in Latin America the market is expected to surge at a pace in terms of revenue over 2025. However, MEA will witness a sluggish growth of the market which is attributed to the lack of initiatives for conductive extensive research and development activities.

Browse more detail information about this report visit at: http://marketgrowthanalysis.com/precision-medicine-market

Read the original here:
Precision Medicine Market Detailed Analysis of Current Industry Figures with Forecasts Growth By 2025 - Crypto News Byte

Further Strengthens Business Development Team with Key Hire

PARSIPPANY, N.J., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences subsidiary, Interpace Pharma Solutions today announced that it is continuing to expand a previously announced partnership agreement to jointly develop, promote and offer translational studies and clinical trial solutions to biotech and pharmaceutical companies with Genecast (Beijing) Biotechnology Co. Ltd (Genecast) of the Peoples Republic of China (PRC). Genecast is a leader in offering diagnostic products and services in the field of oncology and providing a wide range of diagnostic services to pharmaceutical and biotech companies in the PRC. Interpace is sending members of its technical/scientific and business development teams to China this week to begin the tech transfer requirements to support over $3 million of recently secured new business with global pharmaceutical companies.

Michael McCartney, Chief Commercial Officer of Interpace Pharma Solutions commented, We will be joining the Genecast business development team in China to jointly promote our capabilities of tumor profiling testing and clinical testing services in China and will be traveling to Beijing, Suzhou and Shanghai to meet with Genecast pharma customers who are in need of Interpace Pharma Solutions services Mr. McCartney also added We are thrilled to announce the addition of Gordon Vansant, Ph.D. a highly regarded industry expert to our BD team. Dr. Vansant has deep relationships and contacts in China to further strengthen and expand our penetration in China and Asia and will lead our BD efforts in the Southwest US, headquartered out of San Diego.

Du Bo, Co-Founder and CEO of Genecast, said, We are excited that the partnership with Interpace Pharma Solutions is already working and we believe will strengthen our capabilities to provide our customers with high-quality, streamlined one-stop testing services globally. Interpace Pharma Solutions development is in line with our strategy of helping pharmaceutical and biotech companies on a global basis accelerate their biomarker-driven drug development and drive precision medicine forward.

Jack Stover, President & CEO of Interpace Biosciences commented, We are pleased with the new business already being booked as a result of our relationship with such a high-quality partner as Genecast and we are pleased to have such an experienced and successful executive as Dr. Vansant join our Pharma Solutions BD team. We look forward to expanding our partnership with Genecast as well as expanding our international capabilities in Europe, Asia and elsewhere in the near future, concluded Stover.

About Interpace Biosciences

Interpace Biosciences is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Interpace Pharma Solutions is a market leader in providing pharmacogenomics testing, genotyping, and biorepository services to the pharmaceutical and biotech industries. The Biopharma Business also advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

Interpace Diagnostics is a fully integrated commercial and bioinformatics business unit that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP).

For more information, please visit Interpace Biosciences website atwww.interpace.com.

Genecast (Beijing) Biotechnology Co. Ltd.

Genecast is a leader in offering diagnostic products & services in the field of oncology and providing a wide range of diagnostic services to pharmaceutical and biotech companies in the Peoples Republic of China (PRC). Genecasts laboratories have met all applicable standards for accreditation including accreditation from the CAP and earned top marks in a number of external quality assessments carried out by CAP, EMQN, the Clinical Test Center of the National Health Commission of China and Center of Clinical Laboratories of Shanghai.

Genecast has formed collaborations with more than 20 pharmaceutical and biotech companies in providing comprehensive pre-clinical and clinical testing services.

For more information, please visit Genecasts website at http://english.genecast.com.cn.

Media Contact:Dan ChenGenecast (Beijing) Biotechnologychen.dan@genecast.com.cn

Forward Looking Statements on Behalf of Interpace Biosciences

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Companys future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including believes, estimates, anticipates, expects, plans, projects, intends, potential, may, could, might, will, should, approximately or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Companys control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Companys actual results to be materially different from those expressed or implied by any forward-looking statement. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Companys most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other SEC filings. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

INTERPACE CONTACTS:Investor RelationsJoseph Green, Edison Groupjgreen@edisongroup.com

See more here:
Interpace Biosciences Expands Strategic Partnership Activities with Genecast Biotechnology in China - GlobeNewswire

The Ibex Second Read System for breast is now deployed at Maccabi's pathology institute, making it the first lab in the world to implement AI-powered cancer diagnostics for breast biopsies in its routine clinical practice

Tel Aviv, Israel /PRNewswire/ - Ibex Medical Analytics, the pioneer in artificial intelligence (AI)-powered cancer diagnostics, and the KSM Research and Innovation Institute at Maccabi Healthcare Services, announce the deployment of the Ibex Second Read System for breast at Maccabi's pathology institute, the largest pathology lab in Israel.

Ibex Second Read is the first-ever system that detects and grades cancer in breast biopsies. The system uses an artificial intelligence (AI) powered algorithm to analyze cases in parallel to pathologists and compares between the pathologists' diagnoses and the algorithm's findings, subsequently alerting in case of discrepancies with high clinical importance (e.g. a missed cancer). Now used in routine clinical practice, this clinical-grade product enhances the quality control process in the lab and provides a safety net, resulting in decreased diagnostic error rates and a more efficient workflow.

The algorithm used by the Second Read system was developed by Ibex using advanced machine learning techniques and trained on data sets from Maccabi's pathology institute. The institute was the first pathology lab in the world to implement an AI powered cancer diagnostic system in its routine practice - the Ibex Second Read system for prostate which is now deployed in pathology labs worldwide with demonstrated success in detecting missed cancer cases.

"We are proud to roll out a first of a kind product that improves the diagnosis of breast cancer - the most common cancer in women with over 2 million new cases globally each year. The Second Read for breast is a landmark achievement for our team of pathologists, computer scientists and AI specialists and for our partnership with Maccabi Healthcare Services, enabling us to extend the reach of our product suite. The future looks brighter than ever for Ibex, with a growing interest from pathology labs in our products and new tissue types we expect to introduce during 2020" said Joseph Mossel, Ibex Medical Analytics' Co-Founder and CEO.

"We are excited to use the Second Read system for breast cancer detection in our routine practice following a successful research and partnership with Ibex, led by the KSM Research and Innovation Institute. At Maccabi Healthcare Services we are constantly looking for new technologies that can make a real impact on patient care. We believe that adding a security layer to our pathology reporting will improve accuracy levels of our cancer diagnosis, as already proven by the Second Read's prostate module that we have been using in the past 18 months," said Prof. Varda Shalev, Managing Director of the Kahn-Sagol-Maccabi Research and Innovation Institute at Maccabi Healthcare Services.

About Ibex Medical AnalyticsIbex provides the first-ever AI-powered cancer diagnostics solution in routine clinical use in pathology labs, supporting pathologists in delivering accurate, rapid and objective diagnosis of prostate and breast biopsies. Ibex' product is deployed across the laboratory's workflow and builds on deep learning algorithms developed by a team of pathologists, data scientists and software engineers. The company has raised $14 million from prominent VC funds and corporate investors. For more information visit us at http://www.ibex-ai.com.

About Maccabi Healthcare ServicesMaccabi Healthcare Services is one of the world's largest healthcare providers with 2.5 million members. Maccabi has long been recognized, both in Israel and abroad, as a unique and innovative health care system which leads the way in cutting edge medical technology, comprehensive and integrated computerized information systems, costeffective management and sophisticated monitoring and evaluation tools.

The Kahn-Sagol-Maccabi Research and Innovation Institute's vision is to accelerate precision medicine and lead in big data analytics. We aim to increase the amount and quality of medical research being performed at any given moment in Israel and worldwide and partner with the most advanced AI companies to develop innovative, predictive and personalized tools in service of the new era of medicine.

Continued here:
Ibex Medical Analytics And The Kahn-Sagol-Maccabi (KSM) Research And Innovation Institute At Maccabi Healthcare Services Roll Out The First-Ever...

December has always been a time for reflection and anticipation for whats to come the following year. Considering that 2020 marks the beginning of a brand new decade, theres extra excitement for what the year will bring and what tone it will set for the entire decade. It seems that every year is an exciting year for the pharma industry and 2020 stays on course. Pharma professionals have many exciting trends to monitor for the year ahead.

Perhaps the most noteworthy trend of them all is the prevalence of China on the pharma market in the first place. For decades, China has not been a major player certainly no source for meaningful innovation or trendsetting power. This, however, has changed dramatically in the last decade as the government heavily invested in the biopharma industry, which has seen the Chinese market grow by an estimate 25% annually over the course of five years between 2012 and 2016. Current estimations place the value of the market to hit USD $48.8 billion by 2021.

These numbers alone should alert the international community at large to pay attention, especially when it seems that Chinas main priority is the developments in bio-processing with the export of biologics identified as a chief objective.

Preventive healthcare and personalized medicine are also picking up steam. Not every disease can be cured, which is where pharmaceutical innovations strive to prevent its contraction. Perhaps the most significant success that preventive medicine has observes is with HIV. Products like Truvada have made all the difference in slowing down the spread of the virus. This approach is only going to come to the forefront in coming years. In the same breath, the pharmaceutical industry has set its sights on improving health care through personalized medicine, which breaks away from the average and investigates deeper the unique biodome of the patient. The technology relied on full patient data and customized medicines to create a custom-tailored treatment.

Were not in the 21st century, if we dont speak about AI and digitalisation as part of Industry 4.0 in relation to pharmaceuticals. Artificial Intelligence is already poised to become the tool that will win margins and improve budget spending. Its no secret that the pharmaceutical industry is in dire need of improving efficiency in order to reduce its wastefulness and AI is being developed to then handle these processes.

Digital solutions are set to help with breakthroughs in the Value Added Medicines (VAM) sector through an improvement in patient reports. Given the rise of medical wearable technology, it will be easier to collect real patient usage metrics to support VAM players in the long run.

The safest way to gain a deep insight into pharma trends is to attend the trade shows known for a higher commitment to informing its audience about how their professional landscape is changing.

CPhI Worldwide:

Perhaps the first event anyone involved in pharmaceuticals thinks about. The unique feature here is the distinct separation of CPhI Worldwide into six areas that in turn embody each of the pharmaceutical supply chain stages. This allows for more in-depth digging and research into highly specialized trends.

Expopharm: As a leading meeting point for the actors on the global pharmaceutical market, Expopharm presents a full picture of the dynamic market trends and is also a platform for exhibitors to make announcements regarding their personal technological innovations.

MEDICA: Held alongside COMPAMED, MEDICA is the umbrella trade show where the whole of medicine is represented and in that sense youll experience pharmaceutical news and trends in relation to the broader medical and technological fields.

IDS: IDS enjoys a reputation of the most important dentistry trade show in the world, so if youre specialized in dentistry pharmaceuticals IDS is where you need to come to receive highly targeted news, product launches and announcements.

Arab Health: The MENA region has been known for its high-paced rates of innovation and Arab Health is an entry point into a highly competitive market that has its own, entirely different feel. Some trends and innovations are first talked about during this show.

But what about vitamins and supplements?

Adjacent to pharmaceuticals, but not as heavily regulated are the markets for essential supplements and vitamins, which are also in the great throes of transformation for the upcoming year. Were in for the year of watermelon seeds, which have emerged as the surprise super food recently, and a fervent love of all things moringa. The markets that are shaping up to be big earners are the sleep supplements and pet supplements. Whatever you decide to put into your body should be the very best and in that sense its good to have a list of supplement brands that have been recognized for their high quality.

Go here to read the rest:
It's Going to Be a Big Year for Pharma Trends in 2020 Here's What to Watch out For - - VENTS Magazine

Company also announces CRISPR Therapeutics CEO Samarth Kulkarni, Ph.D., Joins its Board of Directors

CAMBRIDGE, Mass. and NEW YORK, Dec. 5, 2019 /PRNewswire/ --Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the completion of an oversubscribed Series C financing of $85 million led by Boxer Capital of the Tavistock Group. Additional new investors Wellington Management Company, BVF Partners L.P., Deerfield Management, funds managed by Janus Henderson Investors, Casdin Capital, and Logos Capital joined current investors Versant Ventures, New Enterprise Associates, RA Capital Management, Nextech Invest, Invus, Perceptive Advisors, City Hill Ventures, and Roche Venture Fund in the round.

Black Diamond Therapeutics Logo (PRNewsfoto/Black Diamond Therapeutics, Inc.)

Proceeds from the Series C financing will be used to support the Company's growth and advance the development of Black Diamond's lead product candidates targeting oncogenic driver mutations of the ErbB kinases in epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). The Company plans to start a combined Phase 1/2 clinical trial of its most advanced product candidate, BDTX-189, in the first half of 2020. The funding will also support the continued expansion of the Company's earlier stage research programs and proprietary Mutation-Allostery-Pharmacology (MAP) platform to identify and target oncogenic mutations. The Company initially operated in stealth mode from New York and from Versant's Basel-based Ridgeline Discovery Engine and has raised $194 million since its founding.

David M. Epstein, President and CEO of Black Diamond commented, "We are privileged to have this impressive syndicate of thought-leading investors share our commitment to patients and support our vision to discover and develop therapies that will potentially transform how cancer is treated. There arecurrently no drugs approved by the FDA to target certain allosteric and other EGFR and HER2 mutations that are prevalent in a variety of cancers with a single therapy, including in patients with deadly cancers like lung cancer or glioblastoma that express these mutations. This funding will help accelerate development of our lead product candidates targeting undrugged oncogenic driver mutations of EGFR and HER2 so that we can get potential new treatments to patients as quickly as possible."

Commenting on the investment, Aaron Davis, CEO of Boxer Capital said, "Black Diamond's ground-breaking MAP platform could revolutionize how we discover and develop new oncology treatments, particularly for some of the most difficult-to-treat cancers. We are delighted to partner with this group of leading investors and experienced management team in this endeavor."

In addition, Black Diamond announced the appointment of Samarth (Sam) Kulkarni, Ph.D., to its Board of Directors. An industry leader with expertise in strategy and operations in biotech and a wide range of pioneering therapeutic technologies, Sam currently serves as CEO of CRISPR Therapeutics AG. Hejoined CRISPR in 2015 in the early stages of the company as Chief Business Officer (CBO), and then served as President and CBO before being named its CEO in 2017.

Story continues

"We are thrilled to have Sam join Black Diamond's Board of Directors. His wealth of experience and proven track record of strategic business accomplishments and advancing innovative therapeutic technologies will be invaluable as we continue to progress our portfolio and design our programs for clinical success," added Dr. Epstein.

Prior to CRISPR, Sam was a partner at McKinsey & Company, where he had a leading role in the Pharmaceutical and Medical products practice. While at McKinsey, he co-led the biotechnology practice and focused on topics ranging from strategy to operations and led initiatives in areas such as personalized medicine and immunotherapy. Sam also serves as the Chairman of the Board of Directors of Casebia Therapeutics, a joint subsidiary formed by CRISPR and Bayer. He received a Ph.D. in bioengineering and nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology. While at the University of Washington, Sam conducted research on the delivery of biological drugs and in the field of molecular diagnostics. He has authored several publications in leading scientific and business journals.

"It is an exciting time to be joining Black Diamond'sBoard of Directors. The Company has tremendous momentum and I believe has significant potential to change how we treat cancer through its MAP platform and discovery engine," said Dr. Kulkarni.

Black Diamond's MAP platformBlack Diamond's Mutation-Allostery-Pharmacology (MAP) platform is built on three central pillars discover, reveal, and target. The Company uses population-level cancer genetic data obtained from all tumor types to identify potential families of mutations that occur within individual oncogenes and rank the mutations for potential oncogenicity. Black Diamond then uses its MAP platform to understand the mechanism for oncogenic activation and its team of experienced medicinal chemists then develops mutation spectrum-selective drugs for the identified targets.

Black Diamond's MAP platform has generated a pipeline of orally available, potent, and selective small molecule kinase inhibitors that target a range of driver mutations in cancer. The Company'sfirst two disclosed programs are targeting groups of EGFR and HER2 allosteric mutants.

About Black DiamondBlack Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company's proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. Black Diamond was founded by David M. Epstein, Ph.D. and Elizabeth Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began building the MAP platform and chemistry discovery engine. For more information please visit http://www.bdtherapeutics.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/black-diamond-therapeutics-closes-85-million-series-c-financing-300969326.html

SOURCE Black Diamond Therapeutics, Inc.

Originally posted here:
Black Diamond Therapeutics Closes $85 Million Series C Financing - Yahoo Finance

The report on the Personalized Medicine Market published by Future Market Insights (FMI) provides a clear understanding of the flight of the Personalized Medicine Market over the forecast period 2016 2026. The study introspects the various factors that are tipped to influence the growth of the Personalized Medicine market in the upcoming years. The current trends, growth opportunities, restraints, and major challenges faced by market players in the Personalized Medicine Market are analyzed in the report.

The study reveals that the global Personalized Medicine Market is projected to reach a market value of ~US$XX and grow at a CAGR of ~XX% during the assessment period. Further, a qualitative and quantitative analysis of the Personalized Medicine Market based on data collected from various credible sources in the market value chain is included in the report along with relevant tables, graphs, and figures.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.futuremarketinsights.co/reports/sample/REP-GB-1511

Key Takeaways of the Report:

The report addresses the following doubts related to the Personalized Medicine Market:

Get Access To TOC Covering 200+ Topics athttps://www.futuremarketinsights.co/toc/REP-GB-1511

Key Players

Some key players in this market are Roche Holding AG, Astra Zeneca PLC, Vertex Pharmaceuticals Inc., Qiagen Inc., BD (Becton Dickinson & Co., Merck & Co. Inc., Pfizer Inc., American Association for Cancer Research, Siemens Healthcare Diagnostics, Inc. among others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on:

Regional analysis includes

North America (U.S., Canada)

Latin America (Mexico. Brazil)

Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)

Eastern Europe (Poland, Russia)

APEJ (China, India, ASEAN, Australia & New Zealand)

Japan

Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint.

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Request Customized Report As Per Your Requirements athttps://www.futuremarketinsights.co/customization-available/REP-GB-1511

Why Choose FMI Research?

About Us

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Contact Us

616 Corporate Way, Suite 2-9018,Valley Cottage, NY 10989,United StatesT: +1-347-918-3531F: +1-845-579-5705T (UK): + 44 (0) 20 7692 8790

Link:
Personalized Medicine Market expected to be valued at ~US$ XX Mn/Bn during the forecast period 2016 2026 - Weekly News Times

While resistance can often make it a challenge to treat mantle cell lymphoma, therapies have come a long way in recent years thanks to the emergence of personalized treatment and the use of BTK inhibitors, according to one expert.

Ruan, a hematologist and oncologist from Weil Cornell Medicine in New York City, recently sat down with OncLive, CUREs sister publication, to discuss the treatment trends in this disease space.

We're moving toward precision medicine and personalized treatment (in MCL), said Ruan. The objective is to overcome resistance and come up with treatment plans that address the underlying disease biology and take personal factors about the patients into consideration.

When asked about the novel agents that are currently showing promise in MCL, Ruan explained that BTK inhibitors have resulted in highoverall response rates (ORRs), more complete remissions (CRs) and a lower number of side effects in this patient population.

Since the approval of Revlimid (lenalidomide) in 2013, a number of newer BTK inhibitors have been approved, with first-generation Imbruvica (ibrutinib) standing out as the top choice for many. So far, this class of agents has the best single-agent activity in MCL to date, explained Ruan. For example, ibrutinib would give about a 65% to 67% ORR, and about 20% of that would be CRs. In contrast, lenalidomide would give you about a 30% ORR and up to about 8% CR.

A newer BTK inhibitor, Calquence (acalabrutinib), is considered just as effective as Imbruvica with an overall response rate of 81% and complete response in 40% of patients who took it during the phase 2 study that led to its approval. That's quite remarkable for a single agent for patients who have relapsed/refractory MCL, Ruan said.

The field continues to grow with the testing of new agents, including BCL-2 inhibitor, Venclexta (venetoclax), which is currently approved in chronic lymphocytic leukemia and other indolent B-cell non-Hodgkin lymphomas. In MCL, we have data to suggest that it has promising activity as a single agent, she said. Currently, it's being studied in combination with a variety of other agents, including BTK inhibitors. They seem to work very well and are helping to move treatment away from chemotherapy.

However, treating MCL can be challenging because of treatment resistance, explained Ruan. All of the agents are being introduced, tested, and approved in the setting of relapsed disease, said Ruan. That is a big challenge for a sizable portion of patients who do not respond maybe they have a genetic mutation that is not responsive to targeted therapy or they develop a secondary mutation in the process of being treated and then they become resistant.

The issue of resistance is important to consider when treating MCL, according to Ruan. We have to provide novel agents that are sensitive to the disease at every stage of the evolution and come up with additional therapies that can overcome the resistance, she said.

In the future, Ruan predicts the shift toward precision medicine and personalized treatment will continue. The objective is to overcome resistance and come up with treatment plans that address the underlying disease biology and take personal factors about the patients into consideration, she said. This is important for us to understand MCL individually.

This precise approach would mean doing more genetic analysis to determine what type of disease is being treated in order to create a treatment plan that would provide the most benefit for the patient.

If we could know (about mutations) ahead of time, we could have the treatment designed and tailored to maximize treatment effectiveness and minimize adverse events, said Ruan.

It doesn't make sense to subject patients to all of the cytotoxicity associated with conventional intensive chemotherapy while other options, such as participation in clinical trials with novel agents, could be very effective.

Go here to see the original:
Precision Medicine and Personalized Treatments Shifting the Tide in Mantle Cell Lymphoma - Curetoday.com

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191118005399/en/

Relevant clinical advances that improve outcomes for patients with glioblastoma have been few and far between over the last two decades, said Frederic Sottilini, CEO of CarThera. Despite multimodal therapy, median survival remains around 15 months for these patients, virtually all of whom recur. Our goal is to optimize the selection and delivery of drug therapies to extend the lives of patients with glioblastoma.

The two companies were brought together by one of the worlds leading neuro-oncology and glioblastoma experts, John de Groot, M.D., professor and chairman ad interim, The University of Texas MD Anderson Cancer Center, who recognized the synergistic nature of their respective clinical initiatives. CarThera is currently conducting a multi-center clinical study of its novel ultrasound technology, SonoCloud-9, designed to increase the permeability of the blood brain barrier to improve the delivery of chemotherapeutic agents to the brains of patients with recurrent glioblastoma. KIYATEC is conducting a multi-center clinical study of its ex vivo 3D cell culture technology to accurately predict pre-treatment, patient-specific response to recommended standard of care cancer drugs for newly diagnosed and recurrent glioblastoma.

As someone who cares for patients with glioblastoma, I applaud the efforts of CarThera and KIYATEC to bring evidence-based advances to the clinic for the purpose of improving outcomes for patients with glioblastoma, said Dr. de Groot. I envision these two technologies as being complementary with the potential to transform the way in which neuro-oncologists manage glioblastoma patients.

Under the terms of the clinical collaboration, KIYATEC will conduct ex vivo drug response profiling on glioblastoma tissue samples from patients enrolled in CarTheras clinical study. CarThera will benefit from having ex vivo drug response profiling for patients enrolled in its study, while KIYATEC will correlate its patient-specific, pre-treatment drug response predictions with actual clinical outcomes of patients in CarTheras study. For both companies, this collaboration represents an opportunity to enrich their portfolios of clinical evidence with the goal of helping clinicians improve outcomes for their patients with glioblastoma.

Both of our companies are dedicated to ensuring that glioblastoma patients receive the most appropriate drug therapy at the right time, and that the efficacy of that therapy is maximized to its fullest therapeutic potential, said Matthew Gevaert, CEO and co-founder of KIYATEC. We believe that this clinical collaboration has the potential to help us accelerate and deliver on the long-awaited promise of personalized medicine for these deserving patients.

Both companies will be sending delegates to the 24th Annual Meeting of the Society for Neuro-Oncology, November 20-24 in Phoenix, Arizona.

About KIYATEC, Inc. KIYATEC leverages its proprietary ex vivo 3D cell culture technology platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors. The companys Drug Development Services business works in partnership with leading biopharmaceutical companies to unlock response dynamics for its investigational drug candidates across the majority of solid tumor types. The companys Clinical Services business is currently engaged in the validation of clinical assays as well as investigator-initiated studies in ovarian cancer, breast cancer, glioblastoma and rare tumors, in its CLIA-certified laboratory. To learn more about KIYATEC, visit http://www.kiyatec.com.

About CarThera CarThera designs and develops innovative therapeutic ultrasound-based medical devices for treating brain disorders. The company is a spin-off from AP-HP, Greater Paris University Hospitals, the largest hospital group in Europe, and Sorbonne University. Since 2010, CarThera has been leveraging the inventions of Professor Alexandre Carpentier, a neurosurgeon at AP-HP who has achieved worldwide recognition for his innovative developments in treating brain disorders. CarThera developed SonoCloud, an intracranial ultrasound implant that temporarily opens the blood-brain barrier (BBB). CarThera is based at the Brain and Spine Institute (Institut du Cerveau et de la Moelle pinire, ICM) in Paris, France, and has laboratories at the Bioparc Lannec business incubator in Lyon, France. The company, led by Frederic Sottilini (CEO), works closely with the Laboratory of Therapeutic Applications of Ultrasound (Laboratoire Thrapie et Applications Ultrasonores, LabTAU, INSERM) in Lyon.www.carthera.eu

View source version on businesswire.com: https://www.businesswire.com/news/home/20191118005399/en/

View post:
CarThera and KIYATEC Collaborate in Effort to Bring Personalized Medicine to Patients Stricken by Brain Cancer - BioSpace

This report provides data on patterns, improvements, target business sectors, materials, limits, and advancements. By thinking from the customers perspective, a team of researchers, forecasters, analysts, and industry experts work carefully to formulate this Global Precision Medicine Market report. Furthermore, it works to determine the impact of buyers, substitutes, new entrants, competitors, and suppliers on the market. This gives more accurate understanding of the market landscape, issues that may affect the industry in the future, and how to best position specific brands. The Global Precision Medicine Market report helps to develop a successful marketing strategy for your business and acts as a backbone to the business.

Global Precision Medicine Marketto grow with a substantial CAGR in the forecast period of 2019-2026. Growing prevalence of cancer worldwide and accelerating demand of novel therapies to prevent of cancer related disorders are the key factors for lucrative growth of market

Key Market Players:

Few of the major competitors currently working in the global precision medicine market areNeon Therapeutics, Moderna, Inc, Merck & Co., Inc, Bayer AG, PERSONALIS INC, GENOCEA BIOSCIENCES, INC., F. Hoffmann-La Roche Ltd, CureVac AG, CELLDEX THERAPEUTICS, BIONTECH SE, Advaxis, Inc, GlaxoSmithKline plc, Bioven International Sdn Bhd, Agenus Inc., Immatics Biotechnologies GmbH, Immunovative Therapies, Bristol-Myers Squibb Company, Gritstone Oncology, NantKwest, Inc among others.

Global Precision Medicine Market By Application (Diagnostics, Therapeutics and Others), Technologies (Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics and Others), Indication (Oncology, Central Nervous System (CNS) Disorders, Immunology Disorders, Respiratory Disorders, Others), Drugs (Alectinib, Osimertinib, Mepolizumab,Aripiprazole lauroxil and Others), Route of Administration (Oral,Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026

Competitive Analysis:

The precision medicine market is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of mass spectrometry market for global, Europe, North America, Asia Pacific and South America.

Market Definition:

Precision medicines is also known as personalized medicines is an innovative approach to the patient care for disease treatment, diagnosis and prevention base on the persons individual genes. It allows doctors or physicians to select treatment option based on the patients genetic understanding of their disease.

According to the data published in PerMedCoalition, it was estimated that the USFDA has approved 25 novels personalized medicines in the year of 2018. These growing approvals annually by the regulatory authorities and rise in oncology and CNS disorders worldwide are the key factors for market growth.

Market Drivers

Market Restraints

Key Developments in the Market:

Competitive Analysis:

Global precision medicine market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global precision medicine market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Market Segmentation:

By technology:-big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics, and others.

By application:- oncology, hematology, infectious diseases, cardiology, neurology, endocrinology, pulmonary diseases, ophthalmology, metabolic diseases, pharmagenomics, and others.

On the basis of end-users:- pharmaceuticals, biotechnology, diagnostic companies, laboratories, and healthcare it specialist.

On the basis of geography:- North America & South America, Europe, Asia-Pacific, and Middle East & Africa. U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others.

In 2017, North America is expected to dominate the market.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:Corporatesales@databridgemarketresearch.com

See original here:
Global Precision Medicine Market Share 2019 Analysis With Observational Studies of Neon Therapeutics, Moderna, Inc, Merck & Co., Inc, Bayer AG,...

For centuries, medicine has largely relied on a single primary source of information for the diagnosis and treatment of disease: individual patients. This data stream has become increasingly complex over time due to advances in imaging, biochemistry and genetics, but it is still patient-based.

Now, a second stream is emerging that I believe is likely to impact the entire healthcare delivery system, both in terms of outcomes and economics: population-based data. The sources of this data could include census records, various government agencies and community health records. The information it provides could span neighborhood and housing conditions, economic stability, education levels, social and community conditions and the availability of healthcare. All of these could contribute to a three-dimensional view of the patient and provide insights into treatment options and the management of chronic conditions. In fact, research (via the National Academy of Medicine) suggests that social determinants account for 80% to 90% of "modifiable contributors to healthy outcomes."

This figure is more than an interesting statistic. It has demonstrable real-world consequences. For example, a Maricopa County, Arizona, program that incorporates social determinants played a significant role in a 67% decrease in suicides in its first three months. The data collected related to poverty, food and housing insecurity, and environmental exposures such as homes with lead paint. Efforts to reduce some of the problems that were discovered, such as delivering meals or installing air conditioners, were likely central to the programs success.

The amount of healthcare data is huge and growing. According to Research and Markets, it more than quadrupled to 700 exabytes from 2013 to 2017 and is projected to triple again to 2,314 exabytes by 2020. Its potential value to businesses is even more impressive. For example, EY estimates that the value of the U.K. National Health Service's datasets could be 5 billion (approximately $6.4 billion) per year and deliver around 4.6 billion (approximately $5.9 billion) of benefit to patients per year in potential operational savings for the NHS, enhanced patient outcomes and generation of wider economic benefits to the U.K.."

New Sources Of Patient Data

The amount of patient-based data is also growing due to new technology developments. Wearables are one prominent source of this new data. The Apple Watch, for example, can monitor and track heart rhythm with a level of sophistication that would have been unimaginable only a few years ago. Glucose monitors can be connected to smartphones to support behavioral changes in patients who need help managing their diabetes.

One of the most exciting developments to me is affordable genome sequencing. It was once a process that cost a thousand dollars or more, but one company recently offered it for $199. Access to this data is a very important development for personalized medicine, especially for cancer patients for whom targeted therapies based on genome analysis could mean the difference between life and death.

Data-Centric Business Models

The explosion in healthcare data has led to a number of data-driven business partnerships. Pfizer collaborated with Flatiron Health to use real-world data in an application for FDA drug approval. In another example, a large insurance provider created an app for smartwatches to help members track their actions so they can receive rewards for activities that improve their well-being. There is also a marketplace for anonymous data. Cloud-based HealthVerity Marketplace, for example, lets customers browse and license data from over 50 billion anonymized transactions.

More partnerships and vertical marketplaces for data will surely emerge over time.

Challenges Ahead

While the idea of data-driven healthcare is widely embraced, putting it into practice is not so simple. There are several barriers to widespread use of statistical data as a new weapon in the ongoing battle against disease.

The technical challenges of collecting and analyzing health data are not trivial. One 2010 survey (viaPR Newswire) conducted for a web-based electronic health record (EHR) company found that the average American patient accumulates records from 18 different providers over a lifetime. The data from many of those visits may be in incompatible formats. In my experience, data collected by governments tends to be in silos as well. As a result, I expect that a considerable amount of data integration work will be required before the data is even ready for analysis.

The twin concerns of privacy and security are also major barriers to data sharing. Generally speaking, patients may be willing to share their health data when it is for a good cause -- such as better outcomes for others. However, there is always the risk that such data will be used to discriminate against people with health conditions. In addition, there is the issue of security -- over 13 million healthcare records were reportedly exposed in breaches in 2018 alone. Another issue is that providers may fear losing a competitive advantage by sharing data.

However, none of these are insurmountable barriers. I believe digital data has enormous potential to influence outcomes for the better and to deliver business value. That potential will not go untapped. Patient data will still be extremely important, but I'm sure it will be enhanced by data from external sources in a win-win model.

Read more from the original source:
How We Can Improve The Healthcare Industry With A Healthy Dose Of Data - Forbes

Todays clinical labs are experiencing a shortage of personnel, but the labs themselves cant slow down.

Value-based healthcare puts a premium on delivering patient outcomes, Timea Zsiray, director of strategy and marketing for Beckman Coulters Workflow and Informational Technology Solutions Business, explained during a press conference at AACC 2019. Clinical labs are an essential part of healthcare, as 65 to 70% of [healthcare] decisions are made based on lab data, she explained.

Consequently, labs have to improve turnaround time while delivering accurate results, she added.

Automation is a promising solution. She pointed out that 32 main steps are typically performed in the lab, most of which are performed manually, and addedthat manual processes are "time consuming and error prone. There is "a need to make lab personnels jobs easier.

However, automation is not just the movement of tubesbut also the digital movement of data, Zsiray.

Healthcare professionals who spoke during the press conference all agreed that healthcare systems are experiencing a shortage of well-trained medical professionals. These speakers included Dr. David Koch, associate professor of pathology at Emory University School of Medicine and director of clinical chemistry, special chemistry, toxicology and point-of-care testing at Grady Memorial Hospital in Atlanta; Dr. Steven H. Wong, professor of pathology and director of the clinical chemistry and toxicology core laboratory, and co-director of the clinical and translational mass spectrometry center at Wake Forest School of Medicine; and Robin Ades, senior regional director of operations for Alverno Laboratories.

Said Koch: We dont have enough people going into the clinical lab profession.

Added Ades: Small- and mid-sized labs have the same staffing issues, especially in rural areas where we dont have the pool of applicants as in the past. And efficiency is expected of all labs, regardless the size. Turnaround time expectations are the same despite the size of the healthcare system, she added.

These professionals are hopeful that automation can help fill the gap. Automation makes it possible to deliver high throughput, Wong said.

Automation has been critical to our success at Grady Hospital in Atlanta, said Koch, adding later that automation helps all staff, even part-time and weekend staff. They have to produce the same high-quality result as the Monday-Friday staff.

Automation may also enable labs to maintain staff engagement. Weve found that we needed our techs doing clinical scientific lab work, not mundane tasks such as specimen processing and loading them into instruments, said Ades. Koch agreed: Graduates want to be involved in meaningful work. Getting the result to the doctor that will benefit the patient is the most important, rather than fussing over minutia that could be handled by automation.

If staff is satisfied and happy, they are more likely to stay, said Wong.

However, todays emerging automation solutions mean more than just moving samples around in a lab. Automation can also contribute to efficiency in processing and results delivery. AutomatedIT allows labs"to be more fail safe in terms of labeling and specimen errors, said Ades. AddedKoch: We can rely on IT to auto-validate much of the data.

To support such automation needs, Beckman Coulters newest solution automates sample handling and more. At AACC Beckman Coulter highlighted WorkflowConnect, WorkflowAdvanced, and WorkflowCommand solutions that are designed to meet the needs of small-, mid-, and high-volume laboratories. It also demonstrated its newest total laboratory automation solution, the DxA 5000, which is intended to improve efficiency through several onboard funtions that help identify and address pre-analytical errors, automate labor-intensive and error-prone laboratory tasks, and auto-verify and release normal results.

The DxA 5000 combines sample-processing hardware with informatics from WorkflowConnect, WorkflowAdvanced, and WorkflowCommand middleware. Tubes are bar coded and after being loaded into the system move through centrifugation and other processes. Data is captured on the status of each sample as it moves through processing, and results are captured and transmitted as soon as available.

Automation used to be moving a tube from A to B, explained Dr. Christoph Moellers, vice president and general manager of Beckman Coulters Workflow and Informational Technology Solutions Business. Now, we receive a tube and deliver a resulteverything in between is automated. We used to focus on push mechanismsa tube comes in and we push it down the line. Now we use a pull mechanismwe pull requests to analyzers to maximize operational throughput.

"We didnt have the software in place before to perform that pull, " he added. Now, "we have that connection in the middleware.

Ades appreciates such capability. Its the scalability of the data flow, she said. The middleware piece is important for us to be standardized across our systems.

In addition, the automated system features a minimum amount of failure points in the system to maintain uptime, Moellers said. He said that Beckman Coulter had interviewed 180 customers globally and found that labs are challenged to maintain short turnaround time with consistent results.

Beckman Coulters solutions are also intended to meet the needs of labs of varying size. We believe in automation for all, so we designed the system to be modular, so we can scale it, he said. Mid-sized hospitals dont always have the buying power or the space in terms of footprint.

Beckman Coulters focus on data could also help it meet the needs of both centralized and decentralized laboratories. I am sure whatever direction [trends go], you need a tool to connect the dots and the data. Thats why informatics is so critical, Moellers said.

Added Koch: The key is that the lab houses the data and provides the data to the clinician. Automated solutions help small and large labs and all those in between.

Wong believes that automation could support emerging diagnostics testing such as multiple-panel biomarker testing, personalized medicine, and genomics and enhance the delivery of that information.

Continue reading here:
Supporting the Digital Movement of Diagnostics Data - Medical Device and Diagnostics Industry

BANGALORE, India, Nov. 18, 2019 /PRNewswire/ -- Molecular diagnostic screening is used to identify different DNA or RNA sequences, including single nucleotide polymorphism (SNP), deletions, rearrangements, insertions, and others for further detection of the disease. These combined methods, such as genome and proteome, helps examine biological markers at the molecular level. These methods are used to treat various infectious diseases

It is expected that technological advances in molecular diagnostics will drive the market dramatically as they allow for greater precision, portability and cost-effectiveness. The launch of MinION, a compact and inexpensive sequencer for users in point-of-care facilities and small peripheral laboratories by Nanopore Technologies, is expected to fuel market growth.

Get Free Sample @ https://reports.valuates.com/request/sample/ALLI-Manu-4H2/molecular_diagnostics_market

Trends Influencing The Molecular Diagnostics Market Share

View Full Report @ https://reports.valuates.com/market-reports/ALLI-Manu-4H2/molecular-diagnostics-market

Region Wise Analysis Of Molecular Diagnostics Market Share

Inquire For Regional/Countries @ https://reports.valuates.com/request/regional/ALLI-Manu-4H2/molecular_diagnostics_market

Key Benefits for Stakeholders

Top Investment Pockets

The global molecular diagnostics market is segmented by application into infectious diseases, oncology, genetic testing, blood screening, and others (microbiology, neurological diseases, and cardiovascular diseases).

Infectious diseases projected the highest revenue in 2016, with a CAGR of 9.3% for the forecast period of 2017-2023, owing to an increase in the number of patients suffering from different viral and bacterial infections, such as Human Immunodeficiency Virus (HIV), Hepatitis C virus(HCV), Human Papillomavirus(HPV), Chlamydia trachomatis/ Neisseria gonorrhoeae (CT/NG), and others. Along with the improving healthcare facilities treating these diseases in the emerging nations.

Molecular Diagnostics Market Key Segments

By Product

By Technology

Inquire for Discount @ https://reports.valuates.com/request/discount/ALLI-Manu-4H2/molecular-diagnostics

By Application

By End Users

By Geography

Buy Report @ https://reports.valuates.com/api/directpaytoken?rcode=ALLI-Manu-4H2

View Similar Reports :

Global Veterinary Molecular Diagnostics Market : https://reports.valuates.com/market-reports/PROF-Auto-33T111/global-veterinary-molecular-diagnostics-market

Global Molecular Diagnostics Systems Market :

https://reports.valuates.com/market-reports/PROF-Auto-14N325/global-molecular-diagnostics-systems-market

Global Molecular Diagnostics and NAT Market :

https://reports.valuates.com/market-reports/PROF-Auto-36L244/global-molecular-diagnostics-and-nat-market

About Us:

Our aim is to collate unparalleled Market insights and notify our customers as and when it happens. Valuates is curating premium Market Research Reports from the leading publishers around the globe. We will help you map your information needs to our report repository of Market research reports and guide you through your purchasing decision. We are based out of Silicon Valley of India (Bengaluru) and provide 24/7 online and offline support to all our customers and just a phone call away.

Contact Us:Valuates Reportssales@valuates.comFor U.S. Toll Free Call +1-(315)-215-3225For IST Call +91-8040957137WhatsApp : +91-9945648335

Website:https://reports.valuates.com

SOURCE Valuates Reports

Read more:
Global Molecular Diagnostics Market Size was Valued at 5,962 Million US$ in 2016 and is Expected to Reach 10,557 Million US$ with a CAGR of 9.1% by...

Here are the top stories covered by DocWire Newsthis week in the Hematology & Oncology section. This week, a report indicated that where you live impacts your chances of surviving lung cancer, ruxolitinib is associated with worsening cardiometabolic health, and more.

Men with theBRCA2mutation have an increased risk ofprostate cancercompared with non-BRCA2carriers and should undergo regular prostate-specific antigen testing, according to interim research from the IMPACT study, presented at the National Cancer Research Institute 2019 Cancer Conference. The results were also published inEuropean Urology.

In the past decade, newlung cancercases have decreased by 19% and five-year survival has increased by 26%, according to a promising report from theAmerican Lung Association. Despite this,lung cancerremains the leading cause of death in the United States, and the chance of surviving the disease is largely dictated by where a person lives.

Secondary surgical cytoreduction followed by chemotherapy does not extend overall survival (primary endpoint) compared with chemotherapy alone in patients with platinum-sensitive, recurrent ovarian cancer, according to a study published inThe New England Journal of Medicine.

Melanoma of the eye may soon be detected using a simple test, according to a study thatappeared inTranslational Vision Science & Technology.

Ruxolitinib, an oral JAK1/2 inhibitor approved by the U.S. Food and Drug Administration for the treatment of myeloproliferative neoplasms, is associated with worseningcardiometabolic health, according to an article published inScientific Reports.

In case you missed it, more hem/onc headlines are featured below:

Continue reading here:
Hem/Onc Roundup: BRCA2 Mutation and Prostate Cancer, Cancer Drug Affects Cardio Health, and more - DocWire News